ArticleCureus2025
Complete Resolution of Granulomatous Rosacea With Topical Ruxolitinib.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy of ruxolitinib cream in a patient with lupus miliaris disseminatus faciei.JAAD case reports · 2026Article
- Imperatorin Mitigates Rosacea-Like Inflammation by Modulating the Crosstalk Between JNK1 and STAT1.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Granulomatous rosacea (GR) is a rare and challenging subtype of rosacea that resists conventional therapies. Here, we present the case of a 56-year-old woman with a two-decade history of treatment-refractory GR who experienced significant clinical improvement with topical ruxolitinib, a Janus kinase (JAK) inhibitor, formulated as a 1.5% cream applied twice daily. After failing multiple established treatments, the patient achieved near-complete resolution of her condition following 10 months of combination therapy with topical ruxolitinib and metronidazole cream. This case highlights the potential efficacy of topical JAK inhibitors as a novel therapeutic approach for recalcitrant GR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.